HRP20210704T1 - Formulacija suhog praška koja sadrži antikolinergik, kortikosteroid i beta-adrenergik za davanje inhalacijom - Google Patents
Formulacija suhog praška koja sadrži antikolinergik, kortikosteroid i beta-adrenergik za davanje inhalacijom Download PDFInfo
- Publication number
- HRP20210704T1 HRP20210704T1 HRP20210704TT HRP20210704T HRP20210704T1 HR P20210704 T1 HRP20210704 T1 HR P20210704T1 HR P20210704T T HRP20210704T T HR P20210704TT HR P20210704 T HRP20210704 T HR P20210704T HR P20210704 T1 HRP20210704 T1 HR P20210704T1
- Authority
- HR
- Croatia
- Prior art keywords
- particles
- powder formulation
- microns
- formulation according
- fraction
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 18
- 238000009472 formulation Methods 0.000 title claims 17
- 239000000843 powder Substances 0.000 title claims 13
- 230000001078 anti-cholinergic effect Effects 0.000 title 1
- 239000003246 corticosteroid Substances 0.000 title 1
- 239000002245 particle Substances 0.000 claims 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims 6
- 239000013543 active substance Substances 0.000 claims 5
- 239000010419 fine particle Substances 0.000 claims 5
- 239000011362 coarse particle Substances 0.000 claims 4
- 229940112141 dry powder inhaler Drugs 0.000 claims 3
- 235000019359 magnesium stearate Nutrition 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000000414 obstructive effect Effects 0.000 claims 2
- RATSWNOMCHFQGJ-TUYNVFRMSA-N (e)-but-2-enedioic acid;n-[2-hydroxy-5-[(1s)-1-hydroxy-2-[[(2s)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 RATSWNOMCHFQGJ-TUYNVFRMSA-N 0.000 claims 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 229950000210 beclometasone dipropionate Drugs 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229960003610 formoterol fumarate dihydrate Drugs 0.000 claims 1
- 210000003918 fraction a Anatomy 0.000 claims 1
- 229960002462 glycopyrronium bromide Drugs 0.000 claims 1
- 229960001375 lactose Drugs 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (12)
1. Formulacija suhog praška za upotrebu u inhalatoru za suhi prašak (DPI) za davanje inhalacijom, rečena formulacija sadrži:
a) frakciju finih čestica koje sadrže smjesu od 90 do 99.5 posto po masi mikroniziranih čestica fiziološki prihvatljivog ekscipijensa i 0.5 do 10 posto po masi magnezijeva stearata, gdje najmanje 90% svih rečenih čestica ima volumni promjer manji od 15 mikrona, i volumni medijalni promjer rečenih čestica je između 3 i 7 mikrona, te ne više od 10% rečenih čestica ima promjer manji od 1.8 mikrona;
b) frakciju grubih čestica koje sadrže fiziološki prihvatljiv ekscipijens koji ima promjer medijalne mase jednak ili veći od 100 mikrona,
pri čemu je omjer između finih čestica a) i grubih čestica b) između 1:99 i 30:70 posto po masi;
c) mikronizirane čestice glikopironijeva bromida, beklometazon-dipropionata, te formoterol-fumarat dihidrata kao aktivnih tvari; pri čemu najmanje 90% mikroniziranih čestica svake aktivne tvari ima volumni promjer jednak ili manji od 6 mikrona, i formulacija isporučuje terapijski učinkovitu dozu svih triju aktivnih tvari između 100 i 500 mikrograma;
gdje se rečena formulacija može dobiti postupkom koji obuhvaća korake i) miješanje čestica ekscipijensa i magnezijeva stearata u visokoenergijskoj aparaturi u periodu manjem od 30 minuta; te ii) miješanje frakcije finih čestica a), frakcije grubih laktoza čestica b) i svih mikroniziranih aktivnih tvari; te pri čemu, nakon isporuke iz inhalatora, formulacija isporučuje frakciju aktivnih čestica u kojima 30% ili više čestica ima veličinu čestice jednaku ili manju od 2.0 mikrona.
2. Formulacija praška prema patentnom zahtjevu 1, naznačeno time da ne više od 10% finih čestica a) ima promjer manji od 1.5 mikrona.
3. Formulacija praška prema patentnom zahtjevu 1 ili 2, naznačeno time da visokoenergijska aparatura jest mehano-fuzijska aparatura.
4. Formulacija praška prema bilo kojem od patentnih zahtjeva 1 do 3, naznačeno time da fiziološki prihvatljiv ekscipijens jest kristalinični šećer.
5. Formulacija praška prema patentnom zahtjevu 4, naznačeno time da se ekscipijens sastoji od alfa-laktoze monohidrata.
6. Formulacija praška prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time da magnezijev stearat oblaže površinu čestica ekscipijensa fine frakcije a) na takav način da je stupanj obloženosti površine najmanje 50%.
7. Formulacija praška prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time da najmanje 90% svih rečenih mikroniziranih čestica aktivnih tvari ima volumni promjer manji od 6.0 mikrona, a volumni medijalni promjer rečenih čestica jest između 1.2 i 2.5 mikrona.
8. Formulacija praška prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time da grube čestice frakcije b) imaju promjer medijalne mase jednak ili veći od 175 mikrona.
9. Formulacija praška prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time da omjer između finih čestica a) i grubih čestica b) jest 10:90 posto po masi.
10. Inhalator za suhi prašak punjen formulacijom suhog praška iz bilo kojeg od patentnih zahtjeva 1 do 10.
11. Formulacija suhog praška prema bilo kojem od patentnih zahtjeva 1 do 10 za upotrebu u sprječavanju i/ili liječenju upalne i/ili opstruktivne bolesti dišnih puteva.
12. Formulacija suhog praška prema patentnom zahtjevu 11, naznačeno time da upalna i/ili opstruktivna bolest dišnih puteva jest kronična opstruktivna plućna bolest (COPD).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13176114 | 2013-07-11 | ||
| EP13194763 | 2013-11-28 | ||
| EP18178893.6A EP3409270B1 (en) | 2013-07-11 | 2014-07-10 | Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210704T1 true HRP20210704T1 (hr) | 2021-06-11 |
Family
ID=51292914
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20182008TT HRP20182008T1 (hr) | 2013-07-11 | 2018-11-29 | Formulacija suhog praška koja sadrži antikolinergik, kortikosteroid i beta-adrenergik za davanje inhalacijom |
| HRP20210704TT HRP20210704T1 (hr) | 2013-07-11 | 2021-05-06 | Formulacija suhog praška koja sadrži antikolinergik, kortikosteroid i beta-adrenergik za davanje inhalacijom |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20182008TT HRP20182008T1 (hr) | 2013-07-11 | 2018-11-29 | Formulacija suhog praška koja sadrži antikolinergik, kortikosteroid i beta-adrenergik za davanje inhalacijom |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US9402825B2 (hr) |
| EP (3) | EP3409270B1 (hr) |
| JP (1) | JP6426167B2 (hr) |
| KR (2) | KR20160029797A (hr) |
| CN (1) | CN105338960B (hr) |
| AU (1) | AU2014289185B2 (hr) |
| BR (1) | BR112015030914B1 (hr) |
| CA (1) | CA2917752C (hr) |
| CL (1) | CL2016000028A1 (hr) |
| CY (2) | CY1120806T1 (hr) |
| DK (2) | DK3409270T3 (hr) |
| EA (1) | EA029125B1 (hr) |
| ES (2) | ES2699986T3 (hr) |
| GE (1) | GEP20186853B (hr) |
| HK (1) | HK1218712A1 (hr) |
| HR (2) | HRP20182008T1 (hr) |
| HU (2) | HUE053957T2 (hr) |
| IL (1) | IL243507A0 (hr) |
| LT (2) | LT3019153T (hr) |
| MX (1) | MX2016000290A (hr) |
| MY (1) | MY176176A (hr) |
| NZ (1) | NZ715797A (hr) |
| PE (2) | PE20212110A1 (hr) |
| PH (1) | PH12016500043A1 (hr) |
| PL (2) | PL3019153T3 (hr) |
| PT (1) | PT3019153T (hr) |
| RS (2) | RS57799B1 (hr) |
| SA (1) | SA516370373B1 (hr) |
| SG (1) | SG11201600110RA (hr) |
| SI (2) | SI3019153T1 (hr) |
| TN (1) | TN2016000007A1 (hr) |
| TW (1) | TWI642450B (hr) |
| UA (1) | UA116907C2 (hr) |
| WO (1) | WO2015004243A1 (hr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011076843A2 (en) * | 2009-12-23 | 2011-06-30 | Chiesi Farmaceutici S.P.A. | Combination therapy for copd |
| RS63952B1 (sr) * | 2012-01-25 | 2023-02-28 | Chiesi Farm Spa | Formulacija suvog praha koja sadrži kortikosteroid i beta-adrenergik, za primenu inhalacijom |
| GEP20186853B (en) * | 2013-07-11 | 2018-05-25 | Chiesi Farma Spa | Dry powder formulation comprising anticholinergic, corticosteroid and beta-adrenergic for administration by inhalation |
| GB201321717D0 (en) * | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Inhalable Medicaments |
| US9554992B2 (en) | 2014-06-09 | 2017-01-31 | Chiesi Farmaceutici S.P.A. | Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic |
| TR201407010A2 (tr) | 2014-06-16 | 2015-12-21 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Vilanterol formülasyonları. |
| JP6600961B2 (ja) * | 2015-03-30 | 2019-11-06 | ブラザー工業株式会社 | 表示制御装置、表示制御方法及び記憶媒体 |
| BR112017023351B1 (pt) * | 2015-05-01 | 2023-11-28 | Board Of Regents, The University Of Texas System | Composição farmacêutica e uso da composição farmacêutica |
| DK3377109T3 (da) * | 2015-11-16 | 2020-04-20 | Chiesi Farm Spa | Fremgangsmåde til fremstilling af en tørpulverformulering, som omfatter anticholinergikum, corticosteroid og beta-adrenergikum |
| LT3377108T (lt) | 2015-11-16 | 2020-07-10 | Chiesi Farmaceutici S.P.A. | Inhaliacinių miltelių kompozicijos, apimančios anticholinerginį agentą, kortikosteroidą ir beta adrenerginį agentą, paruošimo būdas |
| CA3062126C (en) | 2016-11-10 | 2021-04-27 | Medisca Pharmaceutique Inc. | Container assembly and adapter therefor |
| RU2741427C1 (ru) * | 2017-05-11 | 2021-01-26 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Способ получения состава сухого порошка, содержащего антихолинергическое средство, кортикостероид и бета-адренергетик |
| MA48621A (fr) * | 2017-05-11 | 2021-04-28 | Chiesi Farm Spa | Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique |
| CN109200034A (zh) * | 2017-06-30 | 2019-01-15 | 正大天晴药业集团股份有限公司 | 一种可吸入干粉形式的组合物及其制备方法 |
| WO2019060595A1 (en) | 2017-09-20 | 2019-03-28 | Teva Branded Pharmaceutical Products R&D, Inc. | INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM |
| CN114514020A (zh) * | 2019-09-24 | 2022-05-17 | 奇斯药制品公司 | 用于吸入用干粉制剂的新型载体颗粒 |
| US20240050382A1 (en) * | 2022-08-11 | 2024-02-15 | De Motu Cordis Pty Ltd | Inhalable Epinephrine Formulation |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2192866T3 (es) * | 1998-11-13 | 2003-10-16 | Jago Res Ag | Polvo seco para inhalacion. |
| US20070212422A1 (en) * | 1999-11-10 | 2007-09-13 | Manfred Keller | Dry powder for inhalation |
| PE20011227A1 (es) * | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| GB0015043D0 (en) | 2000-06-21 | 2000-08-09 | Glaxo Group Ltd | Medicament dispenser |
| JP5698423B2 (ja) * | 2000-06-27 | 2015-04-08 | ベクトゥラ・リミテッド | 医薬組成物で使用するための粒子の製造法 |
| ES2474199T3 (es) * | 2000-11-30 | 2014-07-08 | Vectura Limited | Composiciones farmacéuticas para inhalaci�n |
| DK1386630T3 (da) | 2002-07-31 | 2006-09-11 | Chiesi Farma Spa | Pulverinhalator |
| JO3102B1 (ar) * | 2004-03-17 | 2017-09-20 | Chiesi Framaceutici S P A | صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة |
| GB0425758D0 (en) * | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
| GB0613161D0 (en) | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| EP1944018A1 (en) * | 2007-01-10 | 2008-07-16 | CHIESI FARMACEUTICI S.p.A. | Micronised particles of low-dosage strength active agents for powder formulations for inhalation |
| WO2011076841A2 (en) | 2009-12-23 | 2011-06-30 | Chiesi Farmaceutici S.P.A. | Combination therapy for copd |
| WO2011076843A2 (en) * | 2009-12-23 | 2011-06-30 | Chiesi Farmaceutici S.P.A. | Combination therapy for copd |
| TR201000681A2 (tr) | 2010-01-29 | 2011-08-22 | B�Lg�� Mahmut | İnhalasyon yoluyla alınan kuru toz formülasyonları. |
| JP5927175B2 (ja) * | 2010-04-01 | 2016-06-01 | シエシー ファルマセウティチィ ソシエタ ペル アチオニ | ドライパウダー状の吸入用医薬組成物、担体粒子および医薬品の製造方法 |
| CA2796934C (en) * | 2010-04-21 | 2018-11-20 | Chiesi Farmaceutici S.P.A. | Process for providing particles with reduced electrostatic charges |
| SG186427A1 (en) * | 2010-06-22 | 2013-01-30 | Chiesi Farma Spa | Dry powder formulation comprising an antimuscarinic drug |
| RS63952B1 (sr) * | 2012-01-25 | 2023-02-28 | Chiesi Farm Spa | Formulacija suvog praha koja sadrži kortikosteroid i beta-adrenergik, za primenu inhalacijom |
| US9393202B2 (en) | 2013-04-26 | 2016-07-19 | Chiesi Farmaceutici S.P.A | Particle size reduction of an antimuscarinic compound |
| GEP20186853B (en) * | 2013-07-11 | 2018-05-25 | Chiesi Farma Spa | Dry powder formulation comprising anticholinergic, corticosteroid and beta-adrenergic for administration by inhalation |
-
2014
- 2014-07-10 GE GEAP201414032A patent/GEP20186853B/en unknown
- 2014-07-10 MX MX2016000290A patent/MX2016000290A/es active IP Right Grant
- 2014-07-10 HU HUE18178893A patent/HUE053957T2/hu unknown
- 2014-07-10 KR KR1020167000719A patent/KR20160029797A/ko not_active IP Right Cessation
- 2014-07-10 KR KR1020217018070A patent/KR102275904B1/ko active IP Right Grant
- 2014-07-10 UA UAA201600204A patent/UA116907C2/uk unknown
- 2014-07-10 ES ES14747855T patent/ES2699986T3/es active Active
- 2014-07-10 PL PL14747855T patent/PL3019153T3/pl unknown
- 2014-07-10 EA EA201690006A patent/EA029125B1/ru unknown
- 2014-07-10 WO PCT/EP2014/064824 patent/WO2015004243A1/en active Application Filing
- 2014-07-10 EP EP18178893.6A patent/EP3409270B1/en active Active
- 2014-07-10 LT LTEP14747855.6T patent/LT3019153T/lt unknown
- 2014-07-10 SG SG11201600110RA patent/SG11201600110RA/en unknown
- 2014-07-10 CA CA2917752A patent/CA2917752C/en active Active
- 2014-07-10 LT LTEP18178893.6T patent/LT3409270T/lt unknown
- 2014-07-10 TN TN2016000007A patent/TN2016000007A1/en unknown
- 2014-07-10 BR BR112015030914-3A patent/BR112015030914B1/pt active IP Right Grant
- 2014-07-10 EP EP19182016.6A patent/EP3569222B1/en active Active
- 2014-07-10 MY MYPI2016000023A patent/MY176176A/en unknown
- 2014-07-10 SI SI201430976T patent/SI3019153T1/sl unknown
- 2014-07-10 TW TW103123763A patent/TWI642450B/zh active
- 2014-07-10 EP EP14747855.6A patent/EP3019153B1/en active Active
- 2014-07-10 ES ES18178893T patent/ES2867552T3/es active Active
- 2014-07-10 SI SI201431806T patent/SI3409270T1/sl unknown
- 2014-07-10 PE PE2021000280A patent/PE20212110A1/es unknown
- 2014-07-10 JP JP2016524826A patent/JP6426167B2/ja active Active
- 2014-07-10 CN CN201480037266.1A patent/CN105338960B/zh active Active
- 2014-07-10 US US14/327,920 patent/US9402825B2/en active Active
- 2014-07-10 NZ NZ715797A patent/NZ715797A/en unknown
- 2014-07-10 DK DK18178893.6T patent/DK3409270T3/da active
- 2014-07-10 RS RS20181254A patent/RS57799B1/sr unknown
- 2014-07-10 RS RS20210320A patent/RS61652B1/sr unknown
- 2014-07-10 DK DK14747855.6T patent/DK3019153T3/en active
- 2014-07-10 PE PE2016000025A patent/PE20160372A1/es unknown
- 2014-07-10 AU AU2014289185A patent/AU2014289185B2/en active Active
- 2014-07-10 PT PT14747855T patent/PT3019153T/pt unknown
- 2014-07-10 HU HUE14747855A patent/HUE039827T2/hu unknown
- 2014-07-10 PL PL18178893T patent/PL3409270T3/pl unknown
-
2016
- 2016-01-07 PH PH12016500043A patent/PH12016500043A1/en unknown
- 2016-01-07 SA SA516370373A patent/SA516370373B1/ar unknown
- 2016-01-07 IL IL243507A patent/IL243507A0/en active IP Right Grant
- 2016-01-08 CL CL2016000028A patent/CL2016000028A1/es unknown
- 2016-05-20 US US15/160,593 patent/US9808422B2/en active Active
- 2016-06-10 HK HK16106687.7A patent/HK1218712A1/zh unknown
-
2018
- 2018-11-01 CY CY181101132T patent/CY1120806T1/el unknown
- 2018-11-29 HR HRP20182008TT patent/HRP20182008T1/hr unknown
-
2021
- 2021-03-12 CY CY20211100219T patent/CY1123937T1/el unknown
- 2021-05-06 HR HRP20210704TT patent/HRP20210704T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210704T1 (hr) | Formulacija suhog praška koja sadrži antikolinergik, kortikosteroid i beta-adrenergik za davanje inhalacijom | |
| HRP20221431T1 (hr) | Formulacija suhog praška koja sadrži antikolinergik, kortikosteroid i beta-adrenergik za davanje inhalacijom | |
| HRP20211598T1 (hr) | Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik | |
| HRP20201711T1 (hr) | Postupci liječenja autoimunih, respiratornih i upalnih poremećaja inhalacijom roflumilast n-oksida | |
| HRP20151214T1 (hr) | Pripravak za inhalaciju koji sadrži aklidinij za lijeäśenje kroniäśne opstruktivne pluä†ne bolesti | |
| HRP20200571T1 (hr) | Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik | |
| RU2014150422A (ru) | Новая дозировка и препаративная форма | |
| JP2013542940A5 (hr) | ||
| JP2016512494A5 (hr) | ||
| RU2013142268A (ru) | Фармацевтическая композиция | |
| JP2009503104A5 (hr) | ||
| CA2796934A1 (en) | Process for providing particles with reduced electrostatic charges | |
| JP2019501876A5 (hr) | ||
| JP2018537453A5 (hr) | ||
| JP2013507429A5 (hr) | ||
| JP2015519356A5 (hr) | ||
| HRP20160630T1 (hr) | Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata | |
| EP2821061B1 (en) | Novel inhalation formulations | |
| RU2015143927A (ru) | Деаморфизация высушенных распылением составов посредством смешивания распылением | |
| CN104644618A (zh) | 一种干粉吸入剂及其制备方法 | |
| EA036153B1 (ru) | Фармацевтическая композиция для ингаляции, упакованная дозированная форма, капсула, способ лечения обструктивных заболеваний дыхательных путей и фармацевтический набор | |
| MY187442A (en) | A pharmaceutical composition containing budesonide and formoterol | |
| Mack et al. | Drug delivery from a novel LAMA/LABA co-suspension technology of glycopyrrolate/formoterol fixed-dose combination MDI: evidence of consistency, robustness and patient-use reliability | |
| Mack et al. | C70 THE NEXT NEW THERAPEUTIC TARGET? TRANSLATIONAL STUDIES OF COPD THERAPIES: Drug Delivery From A Novel Lama/laba Co-Suspension Technology Of Glycopyrrolate/formoterol Fixed-Dose Combination Mdi: Evidence Of Consistency, Robustness And Patient-Use Reliability | |
| MX2017004583A (es) | Composicion farmaceutica que contiene budesonida y formoterol. |